{"id":27921,"date":"2018-12-08T00:51:36","date_gmt":"2018-12-08T00:51:36","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=27921"},"modified":"2018-12-08T00:51:36","modified_gmt":"2018-12-08T00:51:36","slug":"medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/","title":{"rendered":"Medication to prevent anthracycline cardiotoxicity &#8211; Cardiology MCQ &#8211; Answer"},"content":{"rendered":"<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/b9x0oYWSyV8\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/p>\n<h1><span style=\"color: #008000;\">Medication to prevent anthracycline cardiotoxicity &#8211; Cardiology MCQ &#8211; Answer<\/span><\/h1>\n<p><strong><span style=\"color: #0000ff;\">Medication which is universally recommended to prevent anthracycline cardiotoxicity when high dose cancer chemotherapy is planned: Correct answer: 2. Dexrazoxane<\/span><\/strong><\/p>\n<p>Dexrazoxane has been used intravenously to protect the heart against chemotherapeutic agents like doxorubicin.&nbsp;US Food and Drug Administration has approved its use only in adult patients as there was a possible risk of secondary malignancy in pediatric patients. It is a derivative of EDTA and chelates iron so that less number is available to bind with anthracyclines and form superoxide radicals. Concerns have also been raised about its potential interference with antitumor effects of doxorubicin. A recent retrospective cohort study compared the 7 year follow up of those who had received dexrazoxane and a 7.5 year follow up of those who had not received it [1]. Those who received the drug were older and were more likely to receive higher dose of anthracycline chemotherapy and adjuvant trastuzumab treatment.&nbsp;Dexrazoxane treatment was associated with a higher rates leukopenia, neutropenia, anemia and thrombocytopenia. Interestingly, cardiac events were similar in both groups and there was a non significantly lower morality in dexrazoxane group in spite of them being older.<\/p>\n<p><strong><a href=\"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq\/\">Back to question<\/a><\/strong><\/p>\n<h2><span style=\"color: #0000ff;\">Reference<\/span><\/h2>\n<ol>\n<li>Tahover E, Segal A, Isacson R, Rosengarten O, Grenader T, Gips M, Cherny N, Heching NI, Mesika L, Catane R, Gabizon A.&nbsp;<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28562379\">Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival<\/a>.&nbsp;Anticancer Drugs. 2017 Aug;28(7):787-794.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Medication to prevent anthracycline cardiotoxicity &#8211; Cardiology MCQ &#8211; Answer Medication which is universally recommended to prevent anthracycline cardiotoxicity when high dose cancer chemotherapy is planned: Correct answer: 2. Dexrazoxane Dexrazoxane has been used intravenously to protect the heart against chemotherapeutic agents like doxorubicin.&nbsp;US Food and Drug Administration has approved its use only in adult [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":34622,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[2],"tags":[],"class_list":["post-27921","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cardiology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medication to prevent anthracycline cardiotoxicity - Answer<\/title>\n<meta name=\"description\" content=\"Medication to prevent anthracycline cardiotoxicity - Cardiology MCQ - Correct Answer: 2. Dexrazoxane. There is a potential risk of bone marrow suppression.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medication to prevent anthracycline cardiotoxicity - Answer\" \/>\n<meta property=\"og:description\" content=\"Medication to prevent anthracycline cardiotoxicity - Cardiology MCQ - Correct Answer: 2. Dexrazoxane. There is a potential risk of bone marrow suppression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-08T00:51:36+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Medication to prevent anthracycline cardiotoxicity &#8211; Cardiology MCQ &#8211; Answer\",\"datePublished\":\"2018-12-08T00:51:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/\"},\"wordCount\":258,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/\",\"name\":\"Medication to prevent anthracycline cardiotoxicity - Answer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2018-12-08T00:51:36+00:00\",\"description\":\"Medication to prevent anthracycline cardiotoxicity - Cardiology MCQ - Correct Answer: 2. Dexrazoxane. There is a potential risk of bone marrow suppression.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medication to prevent anthracycline cardiotoxicity &#8211; Cardiology MCQ &#8211; Answer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medication to prevent anthracycline cardiotoxicity - Answer","description":"Medication to prevent anthracycline cardiotoxicity - Cardiology MCQ - Correct Answer: 2. Dexrazoxane. There is a potential risk of bone marrow suppression.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/","og_locale":"en_US","og_type":"article","og_title":"Medication to prevent anthracycline cardiotoxicity - Answer","og_description":"Medication to prevent anthracycline cardiotoxicity - Cardiology MCQ - Correct Answer: 2. Dexrazoxane. There is a potential risk of bone marrow suppression.","og_url":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2018-12-08T00:51:36+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Medication to prevent anthracycline cardiotoxicity &#8211; Cardiology MCQ &#8211; Answer","datePublished":"2018-12-08T00:51:36+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/"},"wordCount":258,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/#primaryimage"},"thumbnailUrl":"","articleSection":["Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/","url":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/","name":"Medication to prevent anthracycline cardiotoxicity - Answer","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/#primaryimage"},"thumbnailUrl":"","datePublished":"2018-12-08T00:51:36+00:00","description":"Medication to prevent anthracycline cardiotoxicity - Cardiology MCQ - Correct Answer: 2. Dexrazoxane. There is a potential risk of bone marrow suppression.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/medication-to-prevent-anthracycline-cardiotoxicity-cardiology-mcq-answer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Medication to prevent anthracycline cardiotoxicity &#8211; Cardiology MCQ &#8211; Answer"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/27921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=27921"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/27921\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=27921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=27921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=27921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}